The evidence on peptides — delivered weekly. Subscribe free →

Vilon

unknown risk

Also: Lys-Glu · KE dipeptide

Preliminary Research Only

Vilon is a synthetic dipeptide (Lys-Glu) from the Khavinson bioregulator series representing one of the simplest bioactive peptides under investigation. Despite its minimal structure, studies claim broad immunomodulatory and anti-aging effects.

Molecular Weight
288.3 g/mol
Formula
C11H20N4O5
Common Dosing
1-2 mg/day for 5-10 day courses (from Russian literature)
Category
research
Last Reviewed
2025-01-15

Reported Benefits

Immune Modulation

Preliminary 12 studies

Russian studies show restoration of T-cell counts and NK activity in aging.

Longevity

Preliminary 6 studies

Animal studies report lifespan extension comparable to larger bioregulator peptides.

Mechanism of Action

Vilon is proposed to penetrate cell nuclei and regulate chromatin structure similarly to other bioregulator dipeptides. Despite containing only two amino acids (Lys-Glu), it may interact with transcription factor binding sites to modulate immune gene expression.

Key Clinical Studies

Khavinson VKh et al. (2008)

animal · Aged animals

Immune restoration and lifespan extension with vilon

Overview

Vilon is the simplest peptide in the Khavinson bioregulator series — just two amino acids. The hypothesis that such a minimal structure can exert specific gene regulatory effects in immune tissue is extraordinary and requires extraordinary evidence. The current evidence base, while consistent in direction, does not yet meet that standard.

Dipeptide Bioactivity

The field of bioactive dipeptides and tripeptides is scientifically legitimate — many food-derived peptides with two or three amino acids have documented biological activities. The question for vilon is whether its specific immunomodulatory claims can be validated in rigorous, independently replicated trials.

Comparative Context

Within the bioregulator series, vilon targets the immune system similarly to thymalin and thymosin alpha-1 but represents the minimalist extreme. Whether this minimalism reduces or preserves activity compared to larger preparations is unclear.

Regulatory Status

Research Only

Russian bioregulator dipeptide; no FDA/EMA approval

Safety Profile

Side Effects

  • Injection site reactions (mild)

Contraindications

  • Active autoimmune disease

Drug Interactions

  • Immunosuppressants

Primary Uses

Immune modulationAnti-agingT-cell regulationLongevity

Weekly Briefing

Regulatory updates + new study breakdowns.

For Practitioners

Do you prescribe Vilon?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.